Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen (OGX-011/TV-1011), were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

Custirsen inhibits the production of clusterin, a protein commonly over-produced in cancer cells and a cause of treatment resistance. Two Phase III studies evaluating custirsen in men with castrate-resistant prostate cancer (CRPC) are ongoing: the SYNERGY clinical trial - designed to evaluate an overall survival benefit for custirsen in combination with first-line docetaxel treatment, and the Prostate Cancer SATURN Trial - which will evaluate a durable pain palliation benefit in patients receiving second-line chemotherapy. Both studies are currently enrolling CRPC patients.

Phase II Data Published in Clinical Cancer Research

Data from a Phase II clinical study of custirsen in combination with docetaxel retreatment or mitoxantrone as second-line chemotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) was published in the September 1, 2011 issue of Clinical Cancer Research.

In the clinical study, custirsen combined with docetaxel retreatment resulted in overall survival of 15.8 months. When custirsen was combined with mitoxantrone, overall survival was 11.5 months. The Phase II study also evaluated pain responses in patients with mCRPC. Overall, the pain response was durable (greater than or equal to three months) in 88 percent of patients who had pain or were on opioids for pain at study entry.

"These are encouraging results because we observed durable pain responses in many patients who had di
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 A ... around the world is available from Strategic Consulting, ... companies. “ Industrial Microbiology Market Review, Fourth Edition: ... Market ” (IMMR—4) tracks and compares microbiology test ... North America, Europe and Asia, and forecasts future ...
(Date:8/27/2014)... August 27, 2014 Varian Medical Systems ... its current Salt Lake City manufacturing facility and allow ... Utah to ultimately create 1,000 new full time jobs ... , “Utah is home to hardworking people with immense ... credited with Varian’s success in the manufacturing of our ...
(Date:8/27/2014)... , Aug. 27, 2014   MSC , a ... safety, today announced the appointment of Mary Beth ... With 28 years of experience preparing companies for rapid ... as Executive Vice President of Corporate Development and Healthcare. ... improvement business , as well as corporate strategy and ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3MSC names Mary Beth Loesch President and CEO 2
... Middleton-based Bone Care International Inc. announced on Wednesday that ... , ,Genzyme and Bone Care have signed a definitive agreement ... all-cash transaction valued at $33.00 per fully diluted ... Bone Care's shareholders at a meeting on June 30, and ...
... Perhaps its time to declare 2005 as the Year ... would say its past time. , ,At last ... headline speakers were successful women with words of advice ... included Kay Koplovitz, a South Milwaukee native who launched ...
... today announced that three Wisconsin businesses will receive funding ... Technology Matching Grant (TMG) and Technology Venture Fund (TVF) ... Technologies, Inc., and Bell Brook Labs, LLC, Meanwhile ... merger. , ,Original air date: Saturday, June 18, 2005 ...
Cached Biology Technology:Women entrepreneurs are finding ways to succeed in Wisconsin and beyond 2Women entrepreneurs are finding ways to succeed in Wisconsin and beyond 3
(Date:8/29/2014)... the prolific bloomer Emiliania huxleyi , can grow ... finding contradicts the common view that E. huxleyi ... supplies of thiamine in the ocean to survive. , ... ocean," says CIFAR Senior Fellow Alexandra Worden , ... CIFAR fellows John Archibald (Dalhousie University), ...
(Date:8/29/2014)... them, stretch them, twist them, fold them: modern materials ... technological potential, whether as artificial skin or electronic paper. ... remains a challenge but a new way of working ... be a game-changer. , Previous success in the ... the use of precious gold and silver nanowires. ...
(Date:8/28/2014)... is now available from the Lady Bird Johnson Wildflower ... identifying harmful non-native plant, insect and other invasive species ... cause about $137 billion in economic and other damage ... native plants and more. , "By having streamlined tools ... species occur, we,re more likely to catch these threats ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Copper shines as flexible conductor 2Mobile app makes ID of harmful plants, insects in Texas a snap 2
... at the University of Southampton have taken a significant and important ... meningitis in the UK. Meningitis B (also known as Meningococcal ... meningitis. Each year, an average of 1,870 people in the UK ... from it. Recently the first potentially universal MenB vaccine was ...
... Conopea saotomensis and Conopea fidelis ... islands of So Tom and Prncipe . The ... tropical oceans, but what makes them special is that they occur ... black coral hosts. Observations suggest that the barnacles ...
... Biology Letters found that ship noise affects crab metabolism, ... crabs acclimatise to noise over time. The team from ... to recordings of ship noise showed an increase in metabolic ... have implications for growth and, if the metabolic cost of ...
Cached Biology News:Bridging the gap: Hope that all meningitis strains will be vaccinated for 2Scent of a coral: Symbiosis between 2 new barnacle species and a gorgonian host 2Scent of a coral: Symbiosis between 2 new barnacle species and a gorgonian host 3Ship noise makes crabs get crabby 2
... The new Class II safety cabinets Heraeus ... protection and user-orientated design. ,The new frameless ... the work area. The new front window design ... posture. The large work aperture with a height ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
... orbital shaker stands both present ... ergonomic height, and help protect ... welded tubular steel, these heavy-duty ... the weight and minimize the ...
... polymers) are prepared by ... the enzyme, polynucleotide phosphorylase, ... the appropriate, ribonucleoside diphosphate ... exception of catalog number ...
Biology Products: